These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1194 related items for PubMed ID: 17695303

  • 1. [Clinical analysis of HLA-DR-negative non-M3 AML].
    Mori H, Sakai H, Sanada M, Shimamoto K, Sasaki S, Azuma R, Higuchi T, Harada H, Niikura H, Omine M, Fujita K, Takahashi N.
    Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
    [Abstract] [Full Text] [Related]

  • 2. [Clinicopathological features in HLA-DR-negative acute myeloid leukemia].
    Muroi K, Yoshida M, Suzuki T, Amemiya Y, Hatake K, Miura Y.
    Rinsho Ketsueki; 1997 Aug; 38(8):631-7. PubMed ID: 9311267
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [Abstract] [Full Text] [Related]

  • 5. Acute myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
    Mesárosová A, Hrivnáková A, Babusíková O.
    Neoplasma; 1993 Nov; 40(6):341-5. PubMed ID: 8289964
    [Abstract] [Full Text] [Related]

  • 6. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
    Lewis RE, Cruse JM, Webb RN, Sanders CM, Beason K.
    Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
    [Abstract] [Full Text] [Related]

  • 7. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
    Klobusicka M, Kusenda J, Babusikova O.
    Neoplasma; 2005 Oct; 52(3):211-8. PubMed ID: 15875082
    [Abstract] [Full Text] [Related]

  • 8. [Relationship between immunological characteristics and prognosis in children with acute myeloid leukemia].
    Gu LJ, Tie LJ, Jiang LM, Chen J, Pan C, Dong L, Chen J, Xue HL, Tang JY, Wang YP, Ye H.
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):241-5. PubMed ID: 19374802
    [Abstract] [Full Text] [Related]

  • 9. HLA-Dr negative acute non-lymphocytic leukemia.
    Lazarchick J, Hopkins M.
    Ann Clin Lab Sci; 1998 Apr; 28(3):150-2. PubMed ID: 9646855
    [Abstract] [Full Text] [Related]

  • 10. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
    Liu YR, Chang Y, Ruan GR, Qin YZ, Lai YY, Shi HX, Wang YZ, Li LD, Jiang B, Li JL.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
    [Abstract] [Full Text] [Related]

  • 11. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
    Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadié M, Béné MC.
    Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
    [Abstract] [Full Text] [Related]

  • 12. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
    Zheng J, Wang X, Hu Y, Yang J, Liu J, He Y, Gong Q, Yao J, Li X, Du W, Huang S.
    Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
    [Abstract] [Full Text] [Related]

  • 13. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H.
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [Abstract] [Full Text] [Related]

  • 14. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T, Stevulova L, Kovarikova A, Babusikova O.
    Neoplasma; 2007 Feb; 54(6):471-7. PubMed ID: 17949229
    [Abstract] [Full Text] [Related]

  • 15. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Schmetzer H.
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.
    Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638
    [Abstract] [Full Text] [Related]

  • 17. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A, Bussaglia E, Úbeda J, Facchini L, Aventin A, Sierra J, Nomdedéu JF.
    Hematol Oncol; 2012 Sep 01; 30(3):109-14. PubMed ID: 21812014
    [Abstract] [Full Text] [Related]

  • 18. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
    Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroell T, Pfister K, Schmetzer H.
    Ann Hematol; 2005 May 01; 84(5):287-97. PubMed ID: 15592672
    [Abstract] [Full Text] [Related]

  • 19. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
    Guo QY, Chen BG, Ruan YY, Lin A, Yan WH.
    Leuk Res; 2011 Oct 01; 35(10):1350-4. PubMed ID: 21696824
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 01; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.